ArticleOncoimmunology

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.

Andres Lopez-Albaitero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.